Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool’s free investing community, clinical-stage drug development company Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has earned a respected four-star ranking.
With that in mind, let’s take a closer look at Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||South San Francisco, Calif. (1996)|
|Market Cap||$392.1 million|
|Trailing-12-Month Revenue||$2.3 million|
|Management||Chairman/CEO James Gower |
President/COO Raul Rodriguez
|Return on Equity (average, past 3 years)||(17.6%)|
|Cash/Debt||$298.2 million / $0|
|Competitors||Amgen, Inc. (NASDAQ:AMGN)|
On CAPS, 97% of the 891 members who have rated Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) believe the stock will outperform the S&P 500 going forward.
The street responded to news of mixed results of the OSKIRA-1 phase III trial of fostamatinib … as though the trial was an unequivocal failure. In fact, the trial failed to show improvement over placebo in RA by radiographic criteria but did show stat sig improvement by clinical criteria. If this type of outcome holds through subsequent trials the company and partner AstraZeneca may submit an NDA on the basis that clinical improvement trumps radiographic improvement.
As of the end of 2012, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has about [$300M] in liquid assets to support a market cap of [$392M] at [Friday’s] close. That’s a reasonable bet for a rebound, although my personal preference would have been to let the stock get beaten up further when OSKIRA-2 and OSKIRA-3 results are released later this quarter, and then hopefully mop up closer to cash.
If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its strong four-star rating, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) may not be your top choice.
The article Why Rigel Is Poised to Bounce Back originally appeared on Fool.com and is written by Brian Pacampara.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.